View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 15, 2022

Eurocine and Redbiotec partner to develop HSV-2 vaccines

Redbiotec is entitled to receive royalty payments on Eurocine’s net sales of an approved HSV-2 vaccine.

Eurocine Vaccines has signed a research and partnership agreement with Redbiotec for the development of vaccine candidates against Herpes Simplex Virus Type 2 (HSV-2).

Under the agreement, Eurocine will gain exclusive international rights for developing, producing and marketing the vaccines.

The vaccines will be developed leveraging the Redbiotec’s technologies.

The agreement comprises both a messenger ribonucleic acid (mRNA) and a protein-based technology, its documentation and patents within the HSV-2 field. 

As per the deal, Eurocine will oversee and fund all the activities linked to the development, production and marketing until the signing of an out-licensing agreement with a third party.

The companies will share the proceeds from any out-licensing or granting of rights to third parties in the future, based on the development stage of the project at which the deal with the third party is signed. 

In addition, Redbiotec is entitled to receive royalty payments on Eurocine’s net sales of an approved HSV-2 vaccine.

Furthermore, Eurocine listed the immediate action points after the signing of the latest deal.

The companies will plan the upcoming development, including preclinical and clinical studies, documentation, patents and business development as well as active marketing.

A decision on which technology to pursue, the mRNA or protein-based vaccine candidate will be made.

In addition, the potential of a prophylactic HSV-2 vaccine will be analysed following the development of this therapeutic vaccine and the possible synergies of these vaccines.

Eurocine Vaccines CEO Hans Arwidsson said: “I am very pleased that we have added this promising candidate to our portfolio, especially given the impressive scientific development of the therapeutic vaccine made to this point by Redbiotec. 

“The candidate is perfectly in line with our portfolio strategy.”

A sexually transmitted disease, HSV-2 is currently being treated largely with antivirals and there exists no effective therapeutic vaccine on the market.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology